Legalon-140 capsules №30


Manufacturer: Germany

Poisoning by a pale toadstool.



Legalon-140 Composition
active substance: dry extract of milk thistle fruit (Silybum marianum);

1 capsule contains 173-186.7 mg of dry extract of milk thistle fruit (Silybum marianum) [36-44 1], which corresponds to 140 mg silymarin (DNPH), or 108.2 mg silymarin (HPLC / DAB) in terms of silybinin (solvent – ethyl acetate);

auxiliary substances: microcrystalline cellulose, corn starch, sodium starch (type A), sodium lauryl sulfate, magnesium stearate, iron oxide red E172, iron oxide black E172, titanium dioxide E 171, gelatin.

Legalon-140 Dosage form

Basic physical and chemical properties: hard gelatin capsule size 1. Brown lid without marking, brown body without marking. The contents of the capsule are a homogeneous, compressed brownish-yellow powder.

Legalon-140 Pharmacotherapeutic group
Drugs used to treat liver diseases. Hepatotropic drugs.
ATX code A05B A03.

Legalon-140 Pharmacodynamics
The ability of silymarin to bind free radicals provides its antioxidant activity. Thus, the pathophysiological process of lipid peroxidation, which is responsible for the destruction of cell membranes, is interrupted or prevented. In damaged hepatocytes, silymarin stimulates protein synthesis and normalizes the metabolism of phospholipids, as a result of which silymarin stabilizes cell membranes and limits or prevents the loss of soluble components (in particular transaminases) of liver cells. Silymarin inhibits the penetration of some hepatotoxic substances into the cell (the poison of the pale toadstool). Silymarin enhances protein synthesis by specifically stimulating RNA polymerase A, an enzyme found in the nucleus. This leads to increased production of ribosomal RNAs, and therefore to stimulation of the synthesis of structural and functional proteins (enzymes). As a result, the regenerative ability is improved and the regeneration of liver cells is accelerated.

Absorption – low and slow (half-absorption period – 2.2 hours), metabolized in the liver by conjugation, half-life – 6.3 hours. It is excreted mainly in the bile in the form of glucuronides and sulfates. Does not accumulate in the body. Intestinal-hepatic circulation is noted.

Toxic liver damage for the maintenance treatment of patients with chronic inflammatory liver disease or liver cirrhosis.

Hypersensitivity to the fruits of milk thistle, other components of the drug or to any of the excipients; acute poisoning of various etiologies.

Interaction with other medicinal products and other types of interactions
With the simultaneous use of silymarin in the highest possible doses and oral contraceptives or drugs used in estrogen therapy, the effectiveness of the latter may decrease. By inhibiting the cytochrome P450 system, silymarin thereby enhances the effect of certain drugs, namely: antiallergic drugs (fexofenadine), hypocholesterolemic drugs (lovastatin), anticoagulants (clopidogrel, warfarin), antipsychotic drugs (alprozolam, loraz diazepam) antifungal drugs (ketoconazole), certain cancer drugs (vinblastine).

Application features
Treatment for liver disease will be effective with diet and alcohol avoidance.

Due to the possible estrogen-like effect of silymarin in the highest possible doses, it should be used with caution in patients with hormonal disorders (endometriosis, uterine myoma, breast, ovarian and uterine carcinoma, prostate carcinoma). In these cases, a consultation with a doctor is necessary.

If signs of jaundice appear (skin acquiring a shade from light yellow to dark yellow, yellowing of the whites of the eyes), you should consult your doctor.

The ability to influence the reaction rate when driving or operating machinery
Not noted. If the patient develops any vestibular disorders while taking the drug, refrain from driving or operating machinery.

Use during pregnancy or lactation
There are no data on the efficacy and safety of the drug during pregnancy and lactation, so it should not be prescribed during this period.

Method of administration and dosage
Adults and children over 12 years old take 1 capsule 3 times a day. The capsules should be swallowed whole, without chewing, with a sufficient amount of liquid. The course of treatment is determined by the doctor individually, depending on the nature and course of the disease.

There is insufficient data on the use of this drug in children, so it should not be used in children under 12 years of age.